ABT-737 (navitoclax) inhibits BCL-2 as well as BCL-XL and showed preclinical efficacy; however, its clinical use has been limited due to thrombocytopenia, which is mainly related to the concomitant inhibition of BCL-XL [4]. This evidence concerns the gene BCL2L1 and Thrombocytopenia.